DB06462ExperimentalProtein Based Therapies
Mitumomab, an anti-BEC-2 monoclonal antibody derived from mice, was previously studied to treat small cell lung carcinoma in combination with BCG vaccination.
- Primary indication
- Investigated for use/treatment in lung cancer and melanoma.Curator reviewed
- Also known as
- BEC2
- Code names
- IMC-BEC2
Resolves to
Which companies are running trials of Mitumomab, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account